Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialtypharmaceutical company, announced today that it is has been ranked #37by the Fortune Small Business 100. This marks the third consecutiveyear that Bentley has been included on this list, which appears in theJuly/August issue of FORTUNE Small Business and at www.fsb.com. In2005, Bentley ranked #49. Current rankings are based on three-yearearnings per share, revenue and performance growth.
John A. Sedor, President of Bentley, said, "It's an honor to onceagain be selected and recognized as one of America's fastest growingcompanies by FORTUNE Small Business. We continue to be excited aboutthe direction of the Company as we enter into the 2nd half of 2006. Weremain, focused on maintaining a strong operational and financialposition to support the growth of our specialty generics business andour intranasal insulin development program."
Bentley Pharmaceuticals, Inc. is a specialty pharmaceuticalcompany focused on advanced drug delivery technologies andpharmaceutical products. Bentley's proprietary drug technologiesenhance or facilitate the absorption of pharmaceutical compoundsacross various membranes. Bentley also manufactures a growingportfolio of generic and branded pharmaceuticals in Europe for thetreatment of cardiovascular, gastrointestinal, infectious and CNSdiseases through its subsidiary, Laboratorios Belmac, and marketsthese pharmaceutical products through its subsidiaries, LaboratoriosBelmac, Laboratorios Davur, Laboratorios Rimafar and BentleyPharmaceuticals Ireland; and manufactures and markets activepharmaceutical ingredients through its subsidiary, Bentley API.
Additional information regarding Bentley Pharmaceuticals isavailable on Bentley's web site at www.bentleypharm.com.
Safe Harbor Statement under the Private Securities LitigationReform Act of 1995: This press release contains forward lookingstatements, including without limitation, statements regarding itsongoing operations, the growth of its specialty generics business andits intranasal insulin development program. These forward-lookingstatements are subject to a number of risks and uncertainties thatcould cause actual results to differ materially from future resultsexpressed or implied by such statements. Factors that may cause suchdifferences include, but are not limited to risks associated with thetiming and nature of regulatory approvals, expanding generic andbranded drug operations, changes in third party reimbursement andgovernment mandates affecting pharmaceutical pricing, development andcommercialization of our proprietary products and formulations,competition from other manufacturers of generic and proprietarypharmaceuticals, intellectual property litigation, our relationshipswith our strategic partners, the efficacy and safety of our products,the unpredictability of patent protection, the effects of economicconditions, risks associated with international operations, and otherrisks detailed under Item 1A "Risk Factors" in Bentley's most recentAnnual Report on Form 10-K and its other subsequent periodic reportsfiled with the Securities and Exchange Commission. Bentley cautionsinvestors not to place undue reliance on the forward-lookingstatements contained in this release. These statements speak only asof the date of this document, and Bentley undertakes no obligation toupdate or revise the statements, except as may be required by law.
